First Gastric Cancer Patient Dosed In Clinical Trial Collaboration Evaluating Halozyme’s PEGPH20 In Combination With Anti-PDL1 Immunotherapy
The first gastric cancer patient is receiving doses in the clinical trial collaboration evaluating Halozyme’s PEGPH20 with anti-PDL1 immunotherapy.
Overexpression of MPC1 inhibits the proliferation, migration, invasion, and stem cell-like properties of gastric cancer cells
A new study in Dove Press finds the overexpression of MPC1 inhibits the proliferation, migration, invasion, and stem cell-like properties of gastric cancer... Read More
Bone health in long-term gastric cancer survivors: A prospective study of high-dose vitamin D supplementation using an easy administration scheme.
Physicians evaluated whether high doses of vitamin D after gastric cancer can improve bone health.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
A phase III trial in The Lancet found the addition of rilotumumab (an antibody that targets the hepatocyte growth factor) to chemotherapy... Read More
CMIP is oncogenic in human gastric cancer cells
Researchers find c‑Maf inducing protein (CMIP) could be a novel target in the clinical therapeutic management of gastric cancer.
Global Collaboration Is Key to Progress in Gastroesophageal Cancers
Read up on Oncology Live how international cooperation among specialists is crucial to the advancement of care for gastric cancer patients.
Ramucirumab Shows Promise in Care of Advanced Gastric Cancer
A study published from the Journal of Gastroenterology and Hepatology shows Ramucirumab as a safe and effective treatment of advanced gastric cancer.
Patient Selection for Immunotherapy in Gastric Cancer
Curious about patient selection for immunotherapy in treating gastric cancer? Scientists explain here.
Lumican expression in gastric cancer and its association with biological behavior and prognosis
A new study found an association between lumican expression and invasive potential in gastric cancer and may be an independent prognostic factor.
AKT inhibition is an effective treatment strategy in ARID1A-deficient gastric cancer cells
Researchers look into At-Rich Interactive Domain 1A (ARID1A), which is frequently mutated in gastric cancers with poor prognosis, finding AKT inhibition might... Read More